Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Luc F. Van Gaal, Aila Rissanen, André Scheen et al. · The Lancet · 2005 · 1.5K citations · Full text

Obesity, Metabolic Syndrome, Cannabis Use +10

Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Christian C. Felder, Kelly E. Joyce, Eileen M. Briley et al. · Molecular Pharmacology · 1995 · 876 citations

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Cannabis Use, Molecular Pharmacology, Medicinal Chemistry +15

Cross‐tolerance between delta‐9‐tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212‐2 and anandamide

Roger G. Pertwee, L. A. Stevenson, Greg P. Griffin · British Journal of Pharmacology · 1993 · 111 citations · Full text

Rimonabant Hydrochloride

L.A. Sorbera, J. Castañer, J.S. Silvestre · Drugs of the Future · 2005 · 21 citations